Patheon is expanding its Toronto manufacturing facility, adding 10,000 sq. ft. of GMP space dedicated to the production of oral contraceptives. This includes full-scale commercial production capabilities, including dispensing, granulation, compression, film coating and primary packaging, and has a potential output of 1.3 billion tablets. The new area will use abatement technology, which is used for the elimination of solvent emissions.

The dedicated space for oral contraceptive production fulfills a regulatory requirement needed to sell these products in many countries. This dedicated space also frees up manufacturing capacity in the Toronto facility for current and new business. The expanded Toronto site will be a Center of Excellence for Oral Contraceptives under the company's proprietary Quick to Clinic program.

Terry Novak, president of Patheon North America, stated, "This expansion positions Patheon to compete on a higher level for contract manufacturing opportunities and claim a larger portion of the global oral contraceptive manufacturing market."